Clinical trials: Pediatric Acute-Onset Neuropsychiatric Syndrome
Obsessive-compulsive Disorder With Acute Onset, PANDAS
PANS - A Detailed Study of the Patients, Their Symptoms, Biomarkers and Treatment Offered in a Scandinavian Cohort
Background: Obsessive-compulsive disorder (OCD) is considered one of the most debilitating of the psychiatric illnesses, yet much remains unclear regarding causes and cures.
- Conditions
- Obsessive-compulsive Disorder With Acute Onset, PANDAS, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
- Trial name
- NCT02190292
- Where
- Sweden
- Volunteers
- 185 people
- Sponsor
- Karolinska Institutet
PANS, PANDAS
Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): Clinical Characterization and Prospective Course
This study is a brief (3 month) longitudinal study following children between the ages of 4-16 years old who have been diagnosed with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS).
- Trial name
- NCT04382716
- Testing
- No intervention
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Minnesota
Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)
Background: PANS is an illness that comes on suddenly in children. The full name is Pediatric Acute-Onset Neuropsychiatric Syndrome. It can cause sudden obsessive-compulsive behaviors.
- Trial name
- NCT03507218
- Where
- 8 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Neurodevelopmental Disorders, Autism Spectrum Disorder
Patterns of Neurodevelopmental Disorders
The purpose of this study is to systematically evaluate the results of medical investigations to identify symptom and biological patterns and common etiologies of neurodevelopmental disorders.
- Conditions
- Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome
- Trial name
- NCT06213090
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Richard Frye
PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)
This study investigates the effectiveness of a medicinal cannabis extract (NTI164) with 0.08% THC in treating children with pediatric acute-onset neuropsychiatric syndrome (PANS) over a period of 18 to 54 weeks.
- Trial name
- CannaPANS (NCT06621888)
- Testing
- NTI164
- Where
- 2 sites in Australia
- Volunteers
- 18 people
- Sponsor
- Fenix Innovation Group
PANS, Pediatric Acute-Onset Neuropsychiatric Syndrome
Biomarkers for Diagnosis and Treatment Response in Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)
Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is a complex neuropsychiatric disorder characterized by the abrupt onset of symptoms and currently diagnosed mainly on clinical criteria, as reliable diagnostic biomarkers…
- Trial name
- BIOMA-PANS (NCT07718958)
- Testing
- Psycodiagnostic evaluation, Polysomnography, 1H-NMR analysis
- Where
- 5 sites in Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Cagliari
Post-Acute COVID-19 Syndrome, ME/CFS
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related…
- Conditions
- Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA)
- Trial name
- NCT04806620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Brain Inflammation Collaborative
Pediatric Acute-Onset Neuropsychiatric Syndrome, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections
A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
This study will evaluate the use of intravenous immunoglobulins (IVIG) at a dose of 1g/Kg/body weight given every three weeks for 6 infusions in pediatric subjects ages 4 - 16 years with moderate to severe PANS.
- Trial name
- PANS (NCT03348618)
- Testing
- IVIG
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- IMMUNOe Research Centers
PANDAS, PANS
The Unhide™ Project: Economic Impact Study of IVIG Treatment for PANS
The Economic Impact Study of IVIG treatment for PANS is a part of the Unhide™ Project, which is a research initiative developed by the Brain Inflammation Collaborative.
- Conditions
- PANDAS, PANS, PANS Pediatric Acute-Onset Neuropsychiatric Syndrome, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
- Trial name
- NCT06818656
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Brain Inflammation Collaborative
PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
Open-label Trial of IVIG in Children With PANS
Open-label prospective trial to study efficacy, safety and tolerability of intravenous immunoglobulin (IVIG) once monthly for 6 months in children and adolescents with PANS. Number of subjects: 10. Age range: 4-17 years.
- Trial name
- NCT04609761
- Testing
- Privigen Injectable Product (Intravenous Immunoglobulin)
- Where
- Sweden
- Volunteers
- 17 people
- Sponsor
- Göteborg University
PANS, PANDAS
PEDI Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcus Study
The objective of the Pediatric Epidemiological Data and Incidence (PEDI) PANDAS study is to demonstrate the feasibility of enrollment and retention of subjects in a study to determine the incidence and natural history of children…
- Trial name
- PANDAS (NCT06811935)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Madison
Obsessive-Compulsive Disorder, Treatment Resistant Disorders
Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)
This study evaluates the addition of rituximab to 12 patients diagnosed with treatment resistant obsessive-compulsive disorder in an open trial.
- Trial name
- NCT03983031
- Testing
- Rituximab
- Where
- 2 sites in Sweden
- Volunteers
- 11 people
- Sponsor
- Region Örebro County
Pediatric Acute-Onset Neuropsychiatric Syndrome, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections
Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS
This study is an investigation of the neurologic, immunologic, and rheumatologic markers of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS).
- Conditions
- Pediatric Acute-Onset Neuropsychiatric Syndrome, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections, PANS, PANDAS
- Trial name
- NCT02889016
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Stanford University
COVID-19-Associated Encephalitis, Long COVID
Longterm Influence of Pediatric Long COVID Syndrome
We enroll pediatric patients who were diagnosed COVID-19 for main observation target. We will perform brain MRI and neuropsychiatric evaluation 4-6 months after COVID-19 diagnosed.
- Trial name
- NCT05566392
- Testing
- Brain MRI
- Where
- Taiwan
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Pediatric Acute-Onset Neuropsychiatric Syndrome
Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)
A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome
- Trial name
- NCT04508530
- Testing
- Panzyga
- Where
- 12 sites in United States, Italy and 1 more
- Volunteers
- 71 people
- Sponsor
- Octapharma